Determining the minimum clinically important differences for outcomes in the DOMINO trial.
BACKGROUND: Although less likely to be reported in clinical trials than expressions of the statistical significance of differences in outcomes, whether or not a treatment has delivered a specified minimum clinically important difference (MCID) is also relevant to patients and their caregivers and do...
Main Authors: | Howard, R, Phillips, P, Johnson, T, O'Brien, J, Sheehan, B, Lindesay, J, Bentham, P, Burns, A, Ballard, C, Holmes, C, McKeith, I, Barber, R, Dening, T, Ritchie, C, Jones, R, Baldwin, A, Passmore, P, Findlay, D, Hughes, A, Macharouthu, A, Banerjee, S, Knapp, M, Brown, R, Jacoby, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2011
|
Similar Items
-
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
by: Jones, R, et al.
Published: (2009) -
Donepezil and memantine for moderate-to-severe Alzheimer's disease
by: Howard, R, et al.
Published: (2012) -
Donepezil for the treatment of agitation in Alzheimer's disease.
by: Howard, R, et al.
Published: (2007) -
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).
by: Ballard, C, et al.
Published: (2009) -
Advanced domino 5 : web programming /
by: 239394 Kelleher, Rose M., et al.
Published: (1999)